Pharming Group (PHAR) earnings call transcripts

Management framed the quarter as a transition from Ruconest dependence toward Joenja-led growth, while lowering revenue expectations amid clearer post-launch HAE dynamics.

Management framed Q1 weakness as expected channel normalization and portfolio exits, while emphasizing new growth catalysts for Joenja and resilience in Ruconest’s high-burden segment.

Management framed 2026 as a year of disciplined commercial growth and pipeline milestones, while acknowledging near-term competition and regulatory uncertainty.

Management framed the quarter as evidence of durable commercial growth, with Joenja’s expansion and tighter capital allocation supporting longer-term ambitions.